Clinical Trials Browser

Phase 1/2 × HER2-positive Gastric Cancer × tislelizumab × Clear all

NCT05982834 2023-08-09

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

Phase 1/2 Unknown

Gastrointestinal

HER2-positive Gastric Cancer